Active Ingredient History
Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. Fluvastatin is marketed under the trade names Lescol, Canef, Vastin. LESCOL/LESCOL XL is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD Slow the progression of atherosclerosis in patients with CHD. Fluvastatin selectively and competitively inhibits the hepatic enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate, the rate-limiting step in cholesterol biosynthesis. Inhibition results in a decrease in hepatic cholesterol levels which stimulates the synthesis of LDL receptors and increases hepatic uptake of LDL cholesterol. The end result is decreased levels of plasma total and LDL cholesterol. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adipose Tissue, Brown (Phase 4)
Aging (Phase 2)
Antiphospholipid Syndrome (Phase 2)
Aortic Valve Stenosis (Phase 4)
Atherosclerosis (Phase 4)
Breast Neoplasms (Phase 2)
Cardiovascular Diseases (Phase 3)
Clinical Trial (Phase 4)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Drug Interactions (Phase 4)
Dyslipidemias (Phase 4)
Erectile Dysfunction (Phase 3)
Glioma (Phase 1)
Healthy Volunteers (Phase 1)
Heart Transplantation (Phase 4)
Hepacivirus (Phase 2)
Hepatitis C (Phase 2)
Hepatitis C, Chronic (Phase 2)
Homozygous Familial Hypercholesterolemia (Phase 3)
Hypercholesterolemia (Phase 4)
Hypertension (Phase 4)
Inflammation (Phase 2)
Insulin Resistance (Phase 4)
Kidney Diseases (Phase 3)
Kidney Transplantation (Phase 4)
Lipid Metabolism Disorders (Phase 4)
Livedoid Vasculopathy (Phase 4)
Melanoma (Early Phase 1)
Metabolic Syndrome (Phase 4)
Myocardial Infarction (Phase 4)
Nephritis, Hereditary (Phase 2)
Osteoporosis (Phase 4)
Prostatic Neoplasms (Phase 2)
Proteinuria (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
